These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36781234)

  • 21. Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
    Shitara K; Yuki S; Yoshida M; Takahari D; Utsunomiya S; Yokota T; Sato Y; Inaba Y; Tajika M; Kawai H; Yamaura H; Kato M; Yamazaki K; Komatsu Y; Muro K
    Invest New Drugs; 2012 Apr; 30(2):787-93. PubMed ID: 21174225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial.
    Comella P; Massidda B; Filippelli G; Palmeri S; Natale D; Farris A; De Vita F; Buzzi F; Tafuto S; Maiorino L; Mancarella S; Leo S; Lorusso V; De Lucia L; Roselli M
    Ann Oncol; 2005 Jun; 16(6):878-86. PubMed ID: 15837702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
    Sastre J; Vidaurreta M; Gómez A; Rivera F; Massutí B; López MR; Abad A; Gallen M; Benavides M; Aranda E; Rubio ED;
    Clin Colorectal Cancer; 2013 Dec; 12(4):280-6. PubMed ID: 24012456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of cetuximab in first-line treatment of metastatic colorectal cancer.
    Sotelo MJ; García-Paredes B; Aguado C; Sastre J; Díaz-Rubio E
    World J Gastroenterol; 2014 Apr; 20(15):4208-19. PubMed ID: 24764659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.
    Atreya CE; Ducker GS; Feldman ME; Bergsland EK; Warren RS; Shokat KM
    Invest New Drugs; 2012 Dec; 30(6):2219-25. PubMed ID: 22270257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant Oral Methioninase (o-rMETase) Combined With Oxaliplatinum Plus 5-Fluorouracil Improves Survival of Mice With Massive Colon-Cancer Peritoneal Carcinomatosis.
    Kim MJ; Han Q; Bouvet M; Hoffman RM; Park JH
    Anticancer Res; 2023 Jan; 43(1):19-24. PubMed ID: 36585181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple nanoemulsion system for an oral combinational delivery of oxaliplatin and 5-fluorouracil: preparation and in vivo evaluation.
    Pangeni R; Choi SW; Jeon OC; Byun Y; Park JW
    Int J Nanomedicine; 2016; 11():6379-6399. PubMed ID: 27942212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The addition of bevacizumab to fluoropyrimidine, irinotecan and oxaliplatin-based therapy improves survival for patients with metastatic colorectal cancer (CRC): combined analysis of efficacy.
    Popov I; Milicević M; Radosević-Jelić Lj
    Acta Chir Iugosl; 2008; 55(4):11-6. PubMed ID: 19245134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With
    Rossini D; Antoniotti C; Lonardi S; Pietrantonio F; Moretto R; Antonuzzo L; Boccaccino A; Morano F; Brugia M; Pozzo C; Marmorino F; Bergamo F; Tamburini E; Passardi A; Randon G; Murgioni S; Borelli B; Buonadonna A; Giordano M; Fontanini G; Conca V; Formica V; Aglietta M; Bordonaro R; Aprile G; Masi G; Boni L; Cremolini C
    J Clin Oncol; 2022 Sep; 40(25):2878-2888. PubMed ID: 35666229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa.
    de Bruijn MT; Raats DA; Hoogwater FJ; van Houdt WJ; Cameron K; Medema JP; Borel Rinkes IH; Kranenburg O
    Br J Cancer; 2010 Apr; 102(8):1254-64. PubMed ID: 20354524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
    Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G
    Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group.
    Pfeiffer P; Sorbye H; Qvortrup C; Karlberg M; Kersten C; Vistisen K; Lindh B; Bjerregaard JK; Glimelius B
    Clin Colorectal Cancer; 2015 Sep; 14(3):170-6. PubMed ID: 25956187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group.
    Reinacher-Schick A; Schulmann K; Modest DP; Bruns N; Graeven U; Jaworska M; Greil R; Porschen R; Arnold D; Schmiegel W; Tannapfel A
    BMC Cancer; 2012 Aug; 12():349. PubMed ID: 22876876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.
    Ku GY; Haaland BA; de Lima Lopes G
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):231-8. PubMed ID: 22699811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Weichang'an and 5-fluorouracil suppresses colorectal cancer in a mouse model.
    Tao L; Yang JK; Gu Y; Zhou X; Zhao AG; Zheng J; Zhu YJ
    World J Gastroenterol; 2015 Jan; 21(4):1125-39. PubMed ID: 25632185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan.
    Maitra R; Seetharam R; Tesfa L; Augustine TA; Klampfer L; Coffey MC; Mariadason JM; Goel S
    Oncotarget; 2014 May; 5(9):2807-19. PubMed ID: 24798549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intrahepatic Oxaliplatin and Systemic 5-FU +/- Cetuximab in Chemo-Naïve Patients with Liver Metastases from Colorectal Cancer.
    Larsen FO; Jensen BV; Nørgaard HH; Hermann HK; Larsen PN; Markussen A; Hogdall E; Nielsen D
    Oncology; 2019; 96(6):299-308. PubMed ID: 30999314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study).
    Moriwaki T; Bando H; Takashima A; Yamazaki K; Esaki T; Yamashita K; Fukunaga M; Miyake Y; Katsumata K; Kato S; Satoh T; Ozeki M; Baba E; Yoshida S; Boku N; Hyodo I
    Med Oncol; 2012 Dec; 29(4):2842-8. PubMed ID: 22209842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
    Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
    PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.